Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Receivables (2020 - 2024)

Fulcrum Therapeutics (FULC) has 5 years of Receivables data on record, last reported at $2.1 million in Q4 2024.

  • On a quarterly basis, Receivables rose 290.32% to $2.1 million in Q4 2024 year-over-year; TTM through Dec 2024 was $2.1 million, a 290.32% increase, with the full-year FY2024 number at $2.1 million, up 290.32% from a year prior.
  • Receivables reached $2.1 million in Q4 2024 per FULC's latest filing, up from $537000.0 in the prior quarter.
  • Over the last five years, Receivables for FULC hit a ceiling of $3.6 million in Q4 2021 and a floor of $113000.0 in Q3 2022.
  • A 5-year average of $1.1 million and a median of $706500.0 in 2022 define the central range for Receivables.
  • Peak YoY movement for Receivables: crashed 93.7% in 2022, then skyrocketed 413.27% in 2023.
  • Tracing FULC's Receivables over 5 years: stood at $2.0 million in 2020, then skyrocketed by 81.85% to $3.6 million in 2021, then plummeted by 93.7% to $229000.0 in 2022, then soared by 134.5% to $537000.0 in 2023, then skyrocketed by 290.32% to $2.1 million in 2024.
  • Business Quant data shows Receivables for FULC at $2.1 million in Q4 2024, $537000.0 in Q4 2023, and $580000.0 in Q3 2023.